Interindividual variability in CYP3A‐mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia

Interindividual variability in CYP3A‐mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia

Abstract Venetoclax is a first‐in‐class orally administered B‐cell lymphoma‐2 inhibitor used to treat chronic lymphocytic leukemia (CLL). Venetoclax is primarily metabolized in the liver by cytochrome P450 (CYP) 3A4 to its major metabolite M27, via M5, and M2, M3, and M4 via oxidation. Although vene...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jonghwa Lee, Jessica L. Beers, Isabel Cheng, Vivian Truong, Zachary Brown, Benyam Muluneh, Catherine C. Coombs, Klarissa D. Jackson
Format:	Article
Language:	English
Published:	Wiley 2024-12-01
Series:	Clinical and Translational Science
Online Access:	https://doi.org/10.1111/cts.70106
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)

Efficacy and safety of venetoclax in relapsed/refractory chronic lymphocytic leukemia in Russia routine clinical practice
by: E. A. Dmitrieva, et al.
Published: (2024-09-01)

Case Report: Triplet combination with pirtobrutinib/venetoclax/rituximab in accelerated phase of chronic lymphocytic leukemia
by: Andrea Serafin, et al.
Published: (2025-03-01)

Hybrid histone deacetylase-kinase inhibitor potentiates venetoclax-induced cell death in chronic lymphocytic leukemia
by: Anali Del Milagro Bernabe Garnique, et al.
Published: (2025-04-01)

Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
by: Sandra Soeria-Atmadja, et al.
Published: (2017-01-01)

A common ground: an in silico assessment of the sources of intrinsic ex vivo resistance to venetoclax in acute myeloid leukemia
by: Brunno Gilberto Santos de Macedo, et al.
Published: (2025-04-01)

CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study
by: Heba M. Elmaraghy, et al.
Published: (2025-06-01)

Seasonal timing and interindividual differences in shiftwork adaptation
by: Ruby Kim, et al.
Published: (2025-05-01)

Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice
by: Anna Maria Frustaci, et al.
Published: (2025-06-01)

SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY
by: Naciye Nur Tozluklu, et al.
Published: (2024-12-01)

Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
by: Renshi Kawakatsu, et al.
Published: (2024-02-01)

Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors
by: Jorge Antonio Elias Godoy Carlos, et al.
Published: (2025-04-01)

Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia
by: Fiona C. Brown, et al.
Published: (2025-01-01)

Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
by: Mahesh Tambe, et al.
Published: (2024-10-01)

Intra- and Interindividual Aesthetic Disagreement: A Response to Tooming
by: Anton Killin
Published: (2025-03-01)

Correction: Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
by: Renshi Kawakatsu, et al.
Published: (2025-07-01)

Successful experience of venetoclax in the treatment of refractory primary plasma cell leukemia
by: I. V. Cherkashina, et al.
Published: (2025-03-01)

Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia
by: Yu Cui, et al.
Published: (2024-12-01)

Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia
by: Renshi Kawakatsu, et al.
Published: (2025-01-01)

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net
by: Minoru Kanaya, et al.
Published: (2025-07-01)

Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia
by: Elżbieta Iskierka-Jażdżewska, et al.
Published: (2025-01-01)

Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia
by: Carlos Jiménez-Vicente, et al.
Published: (2025-01-01)

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases
by: Kerry A Rogers, et al.
Published: (2025-04-01)

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
by: Kendall Diebold, et al.
Published: (2025-06-01)

Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
by: Dian Jin, et al.
Published: (2024-07-01)

Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)
by: Heather Klocke, et al.
Published: (2020-01-01)

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
by: Jingying Cui, et al.
Published: (2024-12-01)

Interindividual variability of internal transcribed spacer region of ribosomal DNA in Rotylenchulus reniformis
by: Deng Yanfeng, et al.
Published: (2015-05-01)

Resting-State EEG Microstates Dynamics Associated with Interindividual Vulnerability to Sleep Deprivation
by: Liu Z, et al.
Published: (2024-12-01)

CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
by: Lixiazi He, et al.
Published: (2022-03-01)

Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
by: Di Wu, et al.
Published: (2021-01-01)

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia
by: Wenxiu Shu, et al.
Published: (2025-05-01)

Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia
by: Yi Wang, et al.
Published: (2025-04-01)

Determining dual-task costs and exploring interindividual responsiveness to an opponent using virtual reality
by: S. Pastel, et al.
Published: (2025-03-01)

High interindividual variability of indoxyl sulfate production identified by an oral tryptophan challenge test
by: Ting-Yun Lin, et al.
Published: (2025-01-01)

Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia
by: Bingqian Jiang, et al.
Published: (2025-07-01)

Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia
by: E. V. Usikova, et al.
Published: (2023-01-01)

Older Jehovah’s Witnesses with Acute Myeloid Leukemia: Hypomethylating Agents and Venetoclax as a Transfusion-Sparing Approach
by: Aditi Sharma, et al.
Published: (2025-06-01)

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia
by: Yesid Alvarado-Valero, et al.
Published: (2025-08-01)

Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)
by: Chong Chyn Chua, et al.
Published: (2025-04-01)